 Olaparib: Phase III started - BioCentury.comHome Week in Review Clinical Status Olaparib: Phase III startedOlaparib: Phase III startedAstraZeneca plc LSE:AZN; NYSE:AZN, London, U.K.Product: Olaparib AZD2281, KU-0059436OrganizationsAstraZeneca plcProductsAZD2281KU-0059436Molecular TargetsPolyADP-ribose polymerase PARP 